About Hepatocellular Carcinoma Drugs
HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.
Technavio’s analysts forecast the global hepatocellular carcinoma drugs market to grow at a CAGR of 3.40% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global hepatocellular carcinoma drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in HCC treatment market.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Hepatocellular Carcinoma Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global hepatocellular carcinoma drugs market: Bayer, Eli Lilly, Johnson and Johnson, and Pfizer.
Other Prominent Vendors in the market are: Bristol-Myers Squibb, Celgene, F. Hoffmann-la Roche, Gilead, GlaxoSmithKline, Merck, Novartis, Salix Pharmaceuticals, and Transgene.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is increase in R&D activities for liver cirrhosis medication. The need for efficacious and better-tolerated medications drives R&D in the global liver cirrhosis medication market. The growing incidence of the disease represents significant opportunities for market growth. Companies are working toward the development of drugs that cater to the unmet medical needs for this condition.”
According to the report, one driver in the market is growing cases of hepatitis B and C infections. HCC development has been related with many etiological conditions such as alcohol, hepatitis virus, and cirrhosis. Chronic infection with HBV and HCV often leads to cirrhosis which further enhances the probability of developing HCC. HBV is a DNA virus that integrates into host genome this is believed to be carcinogenic. On the other hand, HCV is an RNA virus, it does not integrate with the host genome however, it still induces HCC through inflammatory response to the virus or through host protein interaction.
Further, the report states that one challenge in the market is stringent government regulations and trial failure in the late stage of drug development. Drug approval processes are stringent worldwide, demanding evidence from clinical trial studies. Regulatory authorities carefully study and evaluate the safety, efficacy, pharmacological data, pharmacodynamic effects, and interactions of drugs before approving them for use. A drug failing any of these criteria is likely to receive a complete response letter (CRL) or face complete rejection from regulatory agencies. On receiving a CRL, a drug applicant is required to furnish any additional data pertaining to the drug, which includes additional clinical trials, thereby increasing the R&D expenditure on the drug.
Bayer, Eli Lilly, Johnson and Johnson, Pfizer, Bristol-Myers Squibb, Celgene, F. Hoffmann-la Roche, Gilead, GlaxoSmithKline, Merck, Novartis, Salix Pharmaceuticals, and Transgene.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook